CeriBell's (CBLL) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• CeriBell's stock has reaffirmed a "sell (e+)" rating by Weiss Ratings, amidst other analysts giving it an average rating of "Moderate Buy" with a target price of $32.14.
• The company's shares increased by 3.7% to $12.24, while possessing a market capitalization of $448.72 million and a negative price-to-earnings ratio of -4.09.
• Insider trading activity shows that CTO Raymond Woo sold 11,112 shares recently, reducing his ownership stake by 6.21%.

CeriBell (NASDAQ:CBLL - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, BTIG Research began coverage on CeriBell in a report on Tuesday, June 24th. They issued a "buy" rating and a $30.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.14.

CeriBell Stock Up 3.7%

Shares of CBLL traded up $0.44 on Wednesday, reaching $12.24. The stock had a trading volume of 248,893 shares, compared to its average volume of 261,018. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The firm has a market capitalization of $448.72 million and a price-to-earnings ratio of -4.09. The company has a 50-day simple moving average of $12.14 and a 200-day simple moving average of $15.35.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.02. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%.The company had revenue of $21.20 million for the quarter, compared to analyst estimates of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. Sell-side analysts predict that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling

In related news, CTO Raymond Woo sold 11,112 shares of the company's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $12.54, for a total transaction of $139,344.48. Following the completion of the sale, the chief technology officer owned 167,704 shares in the company, valued at approximately $2,103,008.16. This represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CBLL. KLP Kapitalforvaltning AS bought a new position in shares of CeriBell in the first quarter worth about $36,000. Tower Research Capital LLC TRC raised its stake in shares of CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after buying an additional 1,801 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after buying an additional 1,256 shares during the period. New York State Common Retirement Fund bought a new position in shares of CeriBell in the first quarter worth about $67,000. Finally, Police & Firemen s Retirement System of New Jersey raised its stake in shares of CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock worth $106,000 after buying an additional 3,502 shares during the period.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.